{"created":"2023-05-15T14:49:53.773875+00:00","id":68309,"links":{},"metadata":{"_buckets":{"deposit":"2fa87017-3648-47ed-87ab-6ac1e0c60fdb"},"_deposit":{"created_by":1,"id":"68309","owners":[1],"pid":{"revision_id":0,"type":"depid","value":"68309"},"status":"published"},"_oai":{"id":"oai:repo.qst.go.jp:00068309","sets":["10:28"]},"author_link":["670615","670619","670622","670626","670621","670623","670617","670624","670627","670618","670614","670620","670612","670625","670616","670613"],"item_10005_date_7":{"attribute_name":"発表年月日","attribute_value_mlt":[{"subitem_date_issued_datetime":"2006-01-28","subitem_date_issued_type":"Issued"}]},"item_10005_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Introduction: \nWe reported that the 4-fraction/1-week carbon ion radiotherapy (CIRT) appeared to be safe and to have a promising potential as a new, radical, and minimally invasive therapeutic option for hepatocellular carcinoma (HCC) at the 2004 ASCO annual meeting. In order to evaluate the safety and efficacy of 2-fraction/2-day CIRT, the next clinical trial was conducted within a phase I/II study between April 2003 and August 2005.\nMethods:\nThe subjects of this report were 32 patients with follow-up period of over 6 months. CIRT was administered in doses of 32.0 to 38.8 cobalt gray equivalent (GyE) in 2 fractions for 2 days in a step-wise dose-escalation study. The median age was 68 (53-80) years. All patients had chronic liver diseases of Child-Pugh grade A in 30 or B in 2. Nine patients had intrahepatic recurrent lesions. The median tumor size was 4.7 (2.0-6.0) cm in diameter. Because no evaluation criteria are available for general hepatic toxicity in the impaired liver, the General Hepatic Toxicity Criteria based on NCI-CTC was defined by the Liver Cancer Working Group.\nResults: \nDuring a median follow-up of 18 (6-28) months, no treatment-related death occurred. Grade 3 hepatic toxicity according to NCI-CTC was observed in one patient in serum-GOT, GPT, T.BIL, and prothrombin activity. Grade 3 general hepatic toxicity occurred in the same one. No other Grade 3 or worse adverse events have occurred. The overall tumor response rate was 91% (29/32) at 6 months after the therapy. One-year and 1.5-year local control rate was 96% (23/24) and 88% (15/17), respectively. One-year and 1.5-year overall survival rate was 100% (24/24) and 94% (17/18), respectively. There were preliminarily no differences in results between the 2-fraction and 4-fraction CIRT.\nConclusion:\nTwo-fraction CIRT for HCC appears preliminarily safe and effective as well as the 4-fraction one. However, further observation is needed because the follow-up period is too short to confirm its clinical efficacy.","subitem_description_type":"Abstract"}]},"item_10005_description_6":{"attribute_name":"会議概要（会議名, 開催地, 会期, 主催者等）","attribute_value_mlt":[{"subitem_description":"2006 Gastrointestinal Cancers Symposium","subitem_description_type":"Other"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"metadata only access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_14cb"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Katou, Hirotoshi"}],"nameIdentifiers":[{"nameIdentifier":"670612","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Yamada, Shigeru"}],"nameIdentifiers":[{"nameIdentifier":"670613","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Yasuda, Shigeo"}],"nameIdentifiers":[{"nameIdentifier":"670614","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Maeda, Yukiteru"}],"nameIdentifiers":[{"nameIdentifier":"670615","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Kamada, Tadashi"}],"nameIdentifiers":[{"nameIdentifier":"670616","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Mizoe, Junetsu"}],"nameIdentifiers":[{"nameIdentifier":"670617","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Ootou, Masao"}],"nameIdentifiers":[{"nameIdentifier":"670618","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Tsujii, Hirohiko"}],"nameIdentifiers":[{"nameIdentifier":"670619","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"加藤 博敏","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"670620","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"山田 滋","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"670621","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"安田 茂雄","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"670622","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"前田 幸輝","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"670623","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"鎌田 正","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"670624","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"溝江 純悦","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"670625","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"大藤 正雄","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"670626","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"辻井 博彦","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"670627","nameIdentifierScheme":"WEKO"}]}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"conference object","resourceuri":"http://purl.org/coar/resource_type/c_c94f"}]},"item_title":"Two-fraction carbon ion radiotherapy for hepatocellular carcinoma: Preliminary results of a phase I/II clinical trial","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Two-fraction carbon ion radiotherapy for hepatocellular carcinoma: Preliminary results of a phase I/II clinical trial"}]},"item_type_id":"10005","owner":"1","path":["28"],"pubdate":{"attribute_name":"公開日","attribute_value":"2006-01-30"},"publish_date":"2006-01-30","publish_status":"0","recid":"68309","relation_version_is_last":true,"title":["Two-fraction carbon ion radiotherapy for hepatocellular carcinoma: Preliminary results of a phase I/II clinical trial"],"weko_creator_id":"1","weko_shared_id":-1},"updated":"2023-05-15T20:27:39.007171+00:00"}